Selling Denervation and Reinnervation to the Same Patient

Duration of effect is not a property of the neurotoxin. It is a property of the patient’s nervous system. We have spent 20 years discussing units, dilution, reconstitution, and serotype as though duration lived in the vial, and almost no time on the biology that actually ends the effect. That biology is now being pharmacologically manipulated by our patients, without our knowledge and usually without our asking.

Over the past 18 months, I have accumulated a cohort of partial nonresponders across onabotulinumtoxinA, abobotulinumtoxinA, daxibotulinumtoxinA, and letibotulinumtoxinA. Adequate dosing, correct anatomy, appropriate technique, unremarkable histories. The common thread, which surfaced only when I began asking directly about it, is regenerative peptide use: BPC-157, TB-500, frequently both, almost always gray market, and almost never volunteered.

Consider what recovery from botulinum neurotoxin type A actually requires. De Paiva and Dolly demonstrated a biphasic repair: the poisoned terminal is bypassed by nerve sprouts that carry transmission first, and only later does the parent terminal resume function, with the sprouts retracting.¹ Clinical duration is therefore a race between SNAP-25 turnover and axonal plasticity. Now consider what we are asking of a patient injecting a peptide whose entire commercial proposition is accelerated tissue repair and angiogenesis, and in the case of thymosin β4, documented enhancement of neurite and axonal outgrowth in injury models. We are administering a drug whose duration depends on the suppression of synaptic remodeling to a patient who is actively buying synaptic remodeling.

The uncomfortable extension is larger than peptides. Our field markets regenerative aesthetics and neuromodulation in the same consultation, to the same face, often in the same visit. One category is sold on its capacity to accelerate repair. The other depends entirely on repair being slow. We have never seriously asked whether these two products are pharmacodynamically antagonistic. That question should make everyone reading this slightly uneasy, because the honest answer is that we do not know, and we have built no infrastructure capable of finding out.

I am not asking anyone to accept my hypothesis. There are at least three competing explanations, and I take them seriously. Peptide users are a hyper-quantified demographic prone to recall bias. Peptide immunomodulation could plausibly favor neutralizing antibody formation. Concurrent glucagon-like peptide-1 (GLP-1)-related therapy, higher muscle mass, and greater expressive muscle activity are all unmeasured confounders. Any of them could be the real answer. Here is the indictment: none of them is captured in your chart either.

So, three asks. Add a regenerative and performance pharmacology field to your intake form, sitting alongside anticoagulants, and populate it with peptides, GLP-1 agonists, testosterone, and NAD+ protocols. Record duration of effect in weeks as a structured data field rather than as a complaint to be absorbed with more units. And press our societies and our industry partners to fund a registry now, before the compounding pathway opens and the denominator becomes unknowable.

We have spent a decade learning how to inject the face. We have spent almost none learning what else is already circulating in it.

Chief Medical Editor